News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zafgen (ZFGN) Appoints Patrick Loustau As President



7/1/2014 8:54:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., July 1, 2014 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced the appointment of Patrick Loustau to the position of President. Mr. Loustau has broad experience in creating and implementing differentiated global and market strategies, from clinical development through life cycle management and business development. Most recently, he was the Senior Vice President for Global Commercialization (Cardiovascular & Metabolics) at Bristol-Myers Squibb, where he built a strong diabetes presence, growing sales from $158M to $1.6B in three years through both organic and external growth strategies that ultimately led to the $7B acquisition of Amylin.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Zafgen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES